-
JNJ-26481585 (Quisinostat) Workflow Guide
2026-09-16
Translate Quisinostat’s potent HDAC inhibition into measurable chromatin, apoptosis, proliferation, and drug-resistance endpoints. This workflow connects TRIM21–ERK1/2 biology with practical cell-based assays while emphasizing solvent control, timing, and orthogonal validation.
-
Annexin V for Time-Resolved Cell Death
2026-09-15
Annexin V is a calcium-dependent phosphatidylserine binding protein that can reveal cell-death timing before DNA fragmentation is readily measurable. This article explains how to translate phosphatidylserine externalization into better apoptosis assay design, controls, and interpretation using recombinant human Annexin V.
-
AT13387 Workflows for Hsp90 Inhibition
2026-09-15
AT13387 supports quantitative Hsp90 inhibition studies that connect client-protein loss with cell cycle arrest and apoptosis induction. This workflow also shows how findings on NINJ1-dependent secretion can improve assay design without overstating evidence for antiviral applications.
-
MMP-2-Responsive Liposomes for Breast Cancer Immunotherapy
2026-09-14
The reference study developed an MMP-2-responsive, cascade-targeted liposome that sequentially delivers the PD-1 pathway-blocking peptide AUNP-12 and the IDO inhibitor NLG919. Its design links tumor accumulation, PD-L1-associated targeting, protease-triggered peptide release, and secondary tumor-cell targeting to remodel an immunosuppressive breast cancer microenvironment.
-
In Situ TIL Therapy with Membrane-Anchored Anti-CD3 mRNA
2026-09-14
The ACS Nano study introduces an in situ TIL therapy in which PEG-optimized lipid nanoparticles deliver mRNA encoding a membrane-anchored anti-CD3 single-chain variable fragment to tumor-associated macrophages and tumor cells. Local expression promoted polyclonal CD8+ TIL activation, expansion, and tumor-cell engagement in mouse tumor models, with enhanced activity when combined with anti-PD-1 therapy.
-
TMEM16F Lipid Scrambling in Ferroptosis and Immunity
2026-09-13
The reference study identifies TMEM16F-mediated plasma-membrane lipid scrambling as a late-stage suppressor of ferroptosis. By linking membrane biophysics to tumor immunology, it shows that blocking this repair-like response increases lytic death, danger-signal release, and responsiveness to PD-1 blockade.
-
Mdivi-1: Mapping DRP1 to Inflammasome Signaling
2026-09-12
Mdivi-1 is a selective DRP1 inhibitor that helps connect mitochondrial fission with apoptosis and NLRP3 inflammasome signaling. This guide translates pulmonary inflammation findings into practical assay design, controls, and interpretation for mitochondrial dynamics research.
-
Recombinant Annexin V Purification for Biophysics
2026-09-11
Burger and colleagues developed a rapid purification workflow for recombinant Annexin V that combines mild osmotic cell opening, reversible calcium-dependent liposome binding, and final ion-exchange chromatography. The approach produced highly pure protein suitable for structural, electrophysiological, and microscopic studies, while illustrating how a phosphatidylserine binding protein can be purified through its native biochemical activity.
-
WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis
2026-09-11
The reference study identifies the WNT5a/GSK3/β-catenin axis as a key regulator of adipogenic drift in skeletal muscle fibro/adipogenic progenitors (FAPs). By combining pharmacological inhibition, mass cytometry, transcriptomics, and in vivo muscle injury models, the authors show that GSK3 blockade and restored WNT5a signaling can suppress fat formation while enhancing FAP support of muscle satellite cell differentiation.
-
Rosemary Extract in Renal Amyloidosis: Mechanistic Evidence
2026-09-10
This study combines amyloid-fibril spectroscopy, MES13 cell experiments, and a mouse model to examine how rosemary ethanol extract may protect against renal amyloidosis. Its findings connect fibril remodeling with calcium and reactive oxygen species control, reduced PERK/ATF-4/CHOP signaling, lower apoptosis, and improved renal pathology.
-
Annexin V-FITC/7-AAD Apoptosis Kit Workflow
2026-09-10
Build a rapid, dual-parameter workflow for separating viable, early apoptotic, late apoptotic, and necrotic cells. Apply it to lactoferrin-processing studies, cell viability assays, and cytotoxicity comparisons while keeping membrane-based evidence distinct from pathway-level conclusions.
-
PBA-Modified PAD4 Inhibitors Block Tumor NETs
2026-09-09
This study developed phenylboronic acid (PBA)-modified PAD4 inhibitors to improve tumor localization and suppress the PAD4-H3cit-NETs pathway in neutrophils. Compound 5i reduced tumor growth and lung metastasis in mouse models while showing limited direct tumor-cell cytotoxicity, supporting a strategy based on tumor targeting and microenvironmental regulation.
-
Dabigatran: From Target Engagement to Assay Meaning
2026-09-09
Dabigatran and Pradaxa are more than direct thrombin inhibitors: they are tools for connecting molecular target engagement with clinically meaningful coagulation data. This evidence-aware guide shows how to interpret assay endpoints, metabolites, matrix effects, and safety implications without confusing laboratory potency with clinical performance.
-
Calcein AM/PI: Making Ferroptosis Translatable
2026-09-08
A mechanistic and translational framework for using Calcein AM/PI live/dead fluorescence to strengthen ferroptosis studies in mammalian cancer models.
-
Melatonin-Tuned LNPs Improve NRF2 mRNA MSC Therapy
2026-09-08
The reference study develops melatonin-tuned lipid nanoparticles that improve cytosolic delivery of Nrf2 mRNA and functionally enhance mesenchymal stem cells for pulmonary fibrosis therapy. Its central contribution is linking lipid membrane fluidity, endosomal escape, antioxidant MSC programming, and reduced fibrotic remodeling within one delivery strategy.